Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)March 26, 2026
Share Facebook Twitter LinkedIn Pinterest Email MetLife outlines record $14B pension risk transfer wins as sales surge 34% in Asia, supported by New Frontier strategy
Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)March 26, 2026
Modiv Industrial outlines accelerated asset recycling, targets 100% manufacturing portfolio within 24 months (NYSE:MDV)March 26, 2026